Search results for " Bone Neoplasms"

showing 10 items of 14 documents

Spinal metastases: Is stereotactic body radiation therapy supported by evidences?

2016

Stereotactic body radiotherapy (SBRT) is becoming widely adopted in the treatment of primary and secondary tumors. Spinal bone metastases are frequently discovered in cancer patients, and in the past have been usually treated with a palliative goal. Nevertheless, in some particular clinical settings, such as oligometastatic patients and/or those with a long life expectancy, spinal SBRT could be considered a valid therapeutic option to obtain long-lasting palliation and, when possible, with a curative goal. This review aims to summarize available clinical and dosimetric data of published studies about spinal SBRT.

medicine.medical_specialtyPalliative careStereotactic body radiation therapymedicine.medical_treatment2720 HematologyBone Neoplasms610 Medicine & healthClinical settingsRadiosurgeryRadiosurgery030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicineDosimetryFractures CompressionPalliative radiotherapymedicineHumansSBRTSpinal NeoplasmsToxicitySpine metastasesbusiness.industryPalliative CareCompressionCancerRadiotherapy DosageHematologymedicine.disease10044 Clinic for Radiation OncologySurgeryTreatment OutcomeOncologyLocal controlDosimetry; Local control; Palliative radiotherapy; SBRT; Spine metastases; Toxicity; Bone Neoplasms; Evidence-Based Practice; Fractures Compression; Humans; Palliative Care; Radiotherapy Dosage; Spinal Fractures; Spinal Neoplasms; Treatment Outcome; Radiosurgery; Hematology; Oncology; Geriatrics and GerontologyEvidence-Based Practice030220 oncology & carcinogenesisSpinal Fractures2730 OncologySecondary tumorsGeriatrics and GerontologySpinal metastasesbusinessFracturesStereotactic body radiotherapyCritical Reviews in Oncology/Hematology
researchProduct

Bone metastases in patients with metastatic renal cell carcinoma: are they always associated with poor prognosis?

2015

Purpose: Aim of this study was to investigate for the presence of existing prognostic factors in patients with bone metastases (BMs) from RCC since bone represents an unfavorable site of metastasis for renal cell carcinoma (mRCC). Materials and methods: Data of patients with BMs from RCC were retrospectively collected. Age, sex, ECOG-Performance Status (PS), MSKCC group, tumor histology, presence of concomitant metastases to other sites, time from nephrectomy to bone metastases (TTBM, classified into three groups: <1 year, between 1 and 5 years and >5 years) and time from BMs to skeletal-related event (SRE) were included in the Cox analysis to investigate their prognostic relevance. R…

OncologyAdultMalemedicine.medical_specialtyCancer ResearchPrognosimedicine.medical_treatmentBone NeoplasmsBone NeoplasmPrognostic factorsMetastasisRenal cell carcinomaRetrospective StudieBone metastasis; Prognostic factors; Renal cell carcinoma; Time to distant metastasis; Cancer Research; OncologyInternal medicineBone metastasis Prognostic factors Renal cell carcinoma Time to distant metastasisCarcinomaMedicineHumansLymph nodeCarcinoma Renal CellSurvival analysisAgedRetrospective StudiesBone metastasis; Prognostic factors; Renal cell carcinoma; Time to distant metastasis; Adult; Aged; Aged 80 and over; Bone Neoplasms; Carcinoma Renal Cell; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Prognosis; Retrospective Studies; Survival Analysis; Cancer Research; OncologyAged 80 and overPrognostic factorTime to distant metastasibusiness.industryResearchTime to distant metastasisBone metastasisKidney NeoplasmBone metastasisMiddle Agedmedicine.diseasePrognosisSurvival AnalysisNephrectomyRenal cell carcinomaKidney Neoplasmsmedicine.anatomical_structureOncologyConcomitantBone metastasiFemaleSurvival AnalysibusinessHumanJournal of Experimental & Clinical Cancer Research
researchProduct

Natural history of malignant bone disease in hepatocellular carcinoma: final results of a multicenter bone metastasis survey

2014

BackgroundBone is an uncommon site of metastasis in patients with advanced hepatocellular carcinoma (HCC). Therefore, there are few studies concerning the natural history of bone metastasis in patients with HCC.Patients and methodsData on clinicopathology, survival, skeletal-related events (SREs), and bone-directed therapies for 211 deceased HCC patients with evidence of bone metastasis were statistically analyzed.ResultsThe median age was 70 years; 172 patients were male (81.5%). The median overall survival was 19 months. The median time to the onset of bone metastasis was 13 months (22.2% at HCC diagnosis); 64.9% patients had multiple bone metastases. Spine was the most common site of bon…

MaleGenetics and Molecular Biology (all)medicine.medical_specialtyCarcinoma HepatocellularBone diseaseSettore MED/06 - Oncologia Medicamedicine.medical_treatmentScienceBone NeoplasmsGastroenterology and HepatologyBiochemistryGastroenterologyBone and BonesMetastasisInternal medicineMedicine and Health SciencesmedicineCarcinomaHumansAged; Bone Neoplasms; Bone and Bones; Carcinoma Hepatocellular; Female; Humans; Italy; Liver; Liver Neoplasms; Male; Middle Aged; Quality of Life; Survival Analysis; Biochemistry Genetics and Molecular Biology (all); Agricultural and Biological Sciences (all)Survival analysisAgedPharmacologyMultidisciplinarybusiness.industryCarcinomaLiver NeoplasmsQRBone metastasisHepatocellularBone fractureMiddle AgedBisphosphonatemedicine.diseaseSurvival Analysiszoledronic acidHepatocellular Carcinomaskeletal-related eventsSurgeryZoledronic acidOncologyItalyLiverAgricultural and Biological Sciences (all)Quality of LifeMedicineFemalebusinessResearch Articlemedicine.drug
researchProduct

Let-7d miRNA Shows Both Antioncogenic and Oncogenic Functions in Osteosarcoma-Derived 3AB-OS Cancer Stem Cells

2015

Osteosarcoma (OS), an aggressive highly invasive and metastatic bone-malignancy, shows therapy resistance and recurrence, two features that likely depend on cancer stem cells (CSCs), which hold both self-renewing and malignant potential. So, effective anticancer therapies against OS should specifically target and destroy CSCs. We previously found that the let-7d microRNA was downregulated in the 3AB-OS-CSCs, derived from the human OS-MG63 cells. Here, we aimed to assess whether let-7d modulation affected tumorigenic and stemness properties of these OS-CSCs. We found that let-7d-overexpression reduced cell proliferation by decreasing CCND2 and E2F2 cell-cycle-activators and increasing p21 an…

Time FactorsEpithelial-Mesenchymal TransitionTime FactorTranscription FactorPhysiologyClinical BiochemistryDrug ResistanceAntineoplastic AgentsApoptosisBone NeoplasmsCell Cycle ProteinsBone NeoplasmTransfectionCell LineAntineoplastic AgentCell MovementCell Line TumorCell Cycle ProteinHumansNeoplasm InvasivenessCell Self RenewalAntineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Bone Neoplasms; Cell Cycle; Cell Cycle Proteins; Cell Line Tumor; Cell Movement; Cell Self Renewal; Drug Resistance Neoplasm; Epithelial-Mesenchymal Transition; Gene Expression Regulation Neoplastic; Humans; MicroRNAs; Neoplasm Invasiveness; Neoplastic Stem Cells; Osteosarcoma; Phenotype; Signal Transduction; Time Factors; Transcription Factors; Transfection; Physiology; Medicine (all); Clinical Biochemistry; Cell BiologyNeoplasm InvasiveneNeoplasticOsteosarcomaTumorApoptosis Regulatory ProteinMedicine (all)Cell CycleApoptosiMicroRNACell BiologyGene Expression Regulation NeoplasticMicroRNAsPhenotypeGene Expression RegulationDrug Resistance NeoplasmNeoplastic Stem CellsNeoplasmNeoplastic Stem CellApoptosis Regulatory ProteinsTranscription FactorsHumanSignal Transduction
researchProduct

Acrometastases to the Hand: A Systematic Review

2021

Background and Objectives: The term acrometastases (AM) refers to secondary lesions sited distally to the elbow and knee, representing 0.1% of all bony metastases. By frequency, pulmonary cancer and gastrointestinal and genitourinary tract neoplasms are the most responsible for the reported AM. Improvements in oncologic patient care favor an increase in the incidence of such rare cases. We performed a systematic review of acrometastases to the hand to provide further insight into the management of these fragile patients. We also present a peculiar case of simultaneous acrometastasis to the ring finger and pathological vertebral fracture. Material and Methods: A literature search according t…

AdultMaleMedicine (General)medicine.medical_specialtyLung NeoplasmsAdolescentmedicine.medical_treatmentBone NeoplasmsWristMetastasisFingersYoung AdultFinger PhalangesR5-920Breast cancerThumb metastasesmedicineCarcinomaChemotherapyHumansChildAgedAged 80 and overRadiotherapyAcrometastasesbusiness.industryGenitourinary systemIncidence (epidemiology)CarcinomaAcrometastases; Carcinoma; Chemotherapy; Immunotherapy; Radiotherapy; Thumb metastases; Adolescent; Adult; Aged; Aged 80 and over; Child; Female; Fingers; Humans; Male; Middle Aged; Prognosis; Young Adult; Bone Neoplasms; Finger Phalanges; Lung NeoplasmsGeneral MedicineMiddle AgedPrognosismedicine.diseasePrimary tumorRadiation therapymedicine.anatomical_structureFemaleSystematic ReviewImmunotherapyRadiologybusinessMedicina
researchProduct

Occupational factors and risk of adult bone sarcomas:a multicentric case-control study in Europe

2006

International audience; We investigated the association between occupational factors and risk of bone sarcoma, a rare tumor with a largely unknown aetiology. A multicentric case-control study was conducted in 7 European countries in 1995-97. Ninety-six cases aged 35-69 years with a centrally reviewed diagnosis of bone sarcoma (68 chondrosarcomas and 28 osteosarcomas) were compared to 2,632 population (68%) or colon cancer (32%) controls. Subjects were interviewed to obtain information on occupational, medical and reproductive history, smoking and alcohol consumption and selected exposures including use of pesticides. Response proportions were 90% among cases and 66% among controls. Odds rat…

MaleCancer ResearchMESH: OsteosarcomaMESH: ReproductionMESH: Occupational Exposure0302 clinical medicineMESH: Risk FactorsRisk FactorsEpidemiologyadult bone sarcomasOdds Ratio030212 general & internal medicineeducation.field_of_studyOsteosarcomaMESH: Middle AgedReproductionResearch Support Non-U.S. Gov'tSmokingMESH: ChondrosarcomaMiddle AgedMESH: Bone NeoplasmsMESH: Interviews as TopicMESH: Case-Control Studies3. Good healthEuropeMulticenter StudyOncology030220 oncology & carcinogenesisColonic NeoplasmsFemaleSarcomamulticentric case-control studyAdultmedicine.medical_specialtyMESH: SmokingAlcohol DrinkingPopulationChondrosarcomaBone NeoplasmsBone SarcomaOccupational medicineInterviews as Topic03 medical and health sciencesInternal medicineOccupational ExposuremedicineJournal ArticlewoodworkersHumansComparative StudyRisk factoreducationMESH: Colonic NeoplasmsMESH: Humansbusiness.industryCase-control studyoccupational risk factorsMESH: AdultOdds ratiopesticidesmedicine.diseaseMESH: MaleMESH: Odds RatioSurgery[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologieCase-Control Studies[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieMESH: EuropebusinessMESH: FemaleMESH: Alcohol Drinking
researchProduct

Natural history of bone metastasis in colorectal cancer: final results of a large Italian bone metastases study.

2012

ABSTRACT Background Data are limited regarding bone metastases from colorectal cancer (CRC). The objective of this study was to survey the natural history of bone metastasis in CRC. Patients and methods This retrospective, multicenter, observational study of 264 patients with CRC involving bone examined cancer treatments, bone metastases characteristics, skeletal-related event (SRE) type and frequency, zoledronic acid therapy, and disease outcomes. Results Most patients with bone metastases had pathologic T3/4 disease at CRC diagnosis. The spine was the most common site involved (65%), followed by hip/pelvis (34%), long bones (26%), and other sites (17%). Median time from CRC diagnosis to b…

Oncologymedicine.medical_specialtyBone Density Conservation AgentSettore MED/06 - Oncologia MedicaColorectal cancerBone NeoplasmsColorectal NeoplasmBone Neoplasmdrug therapy/pathologyZoledronic AcidInternal medicinemedicineHumansImidazolePelvisRetrospective Studiesdrug therapy/secondarybone metastases colorectal cancer zoledronic acidBone Density Conservation AgentsDiphosphonatesbusiness.industryImidazolesBone metastasisCancerRetrospective cohort studyHematologymedicine.diseaseNatural historyBone Density Conservation AgentsZoledronic acidmedicine.anatomical_structureDiphosphonateOncologytherapeutic useBone Density Conservation Agents; therapeutic use; Bone Neoplasms; drug therapy/secondary; Colorectal Neoplasms; drug therapy/pathology; Diphosphonates; Humans; Imidazoles; Retrospective StudiesbusinessColorectal NeoplasmsHumanmedicine.drug
researchProduct

MMP-2, MMP-9 and activin A blood levels in patients with breast cancer or prostate cancer metastatic to the bone.

2007

Background: The clinical significance of the circulating levels of activin A and matrix metalloproteinase-2 (MMP-2) and -9 (MMP-9) was investigated in patients with breast cancer (BC) or prostate cancer (PC) with (M1) or without (M0) bone metastasis. Patients and Methods: MMP-2, MMP-9 and activin A blood concentrations were measured by enzyme immunoassays in 79 cancer patients and in 57 healthy blood donors (HS) who served as a control group. The diagnostic accuracy of these molecules to discriminate between M0 and M1 patients was evaluated by the receiver operating characteristic curve (ROC) and compared to that of tumor markers CA15.3 or prostate-specific antigen (PSA). Results: Activin A…

AdultAged 80 and overMaleMucin-1Prostatic NeoplasmsBone NeoplasmsBreast NeoplasmsMiddle AgedActivinsActivin Breast Cancer Bone metastasis proteinasesMatrix Metalloproteinase 9Activins; Adult; Aged; Aged 80 and over; Bone Neoplasms; Breast Neoplasms; Female; Humans; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Middle Aged; Mucin-1; Prostatic NeoplasmsHumansMatrix Metalloproteinase 2FemaleAged
researchProduct

MicroRNA-29b-1 impairs in vitro cell proliferation, self‑renewal and chemoresistance of human osteosarcoma 3AB-OS cancer stem cells

2014

Osteosarcoma (OS) is the most common type of bone cancer, with a peak incidence in the early childhood. Emerging evidence suggests that treatments targeting cancer stem cells (CSCs) within a tumor can halt cancer and improve patient survival. MicroRNAs (miRNAs) have been implicated in the maintenance of the CSC phenotype, thus, identification of CSC-related miRNAs would provide information for a better understanding of CSCs. Downregulation of miRNA-29 family members (miR-29a/b/c; miR‑29s) was observed in human OS, however, little is known about the functions of miR-29s in human OS CSCs. Previously, during the characterization of 3AB-OS cells, a CSC line selected from human OS MG63 cells, we…

cancer stem cellsHomeobox protein NANOGCancer Research3AB-OS cells; Cancer stem cells; MicroRNA; MicroRNA-29b-1; Multidrug resistance; Osteosarcoma; Bone Neoplasms; Cell Line Tumor; Cell Movement; Cell Proliferation; Drug Resistance Neoplasm; Gene Expression Regulation Neoplastic; Humans; MicroRNAs; Neoplasm Invasiveness; Osteosarcoma; Cancer Research; OncologyDrug ResistanceBone NeoplasmsBiologyCell LineSOX2multidrug resistanceCell MovementCancer stem cellCell Line TumorSettore BIO/10 - BiochimicamicroRNAmedicineHumansNeoplasm InvasivenessClonogenic assaymicroRNA-29b-1Cell ProliferationNeoplasticOsteosarcomaTumormicroRNAOncogeneCancer3AB-OS cellsArticlesCell cyclemedicine.diseaseGene Expression Regulation Neoplasticosteosarcoma cancer stem cells microRNA microRNA-29b-1 multidrug resistance 3AB-OS cellsMicroRNAsGene Expression RegulationOncologyDrug Resistance NeoplasmImmunologyCancer researchNeoplasm
researchProduct

New molecular targets in bone metastases.

2010

Bone metastases have a major impact on morbidity and on mortality in cancer patients. Despite its clinical relevance, metastasis remains the most poorly elucidated aspect of carcinogenesis. The biological mechanisms leading to bone metastasis establishment have been referred as " vicious circle," a complex network between cancer cells and the bone microenvironment. This review is aimed to underline the new molecular targets in bone metastases management other than bisphosphonates. Different pathways or molecules such as RANK/RANKL/OPG, cathepsin K, endothelin-1, Wnt/DKK1, Src have recently emerged as potential targets and nowadays preclinical and clinical trials are underway. The results fr…

Oncologymedicine.hormonemedicine.medical_specialtyPathologyCathepsin KProto-Oncogene Proteins pp60(c-src)Antineoplastic AgentsBone NeoplasmsBone NeoplasmAntibodies Monoclonal HumanizedEndothelinMetastasisAntineoplastic AgentEndothelinsBone metastases; Molecular targets; Animals; Antibodies Monoclonal; Antibodies Monoclonal Humanized; Antineoplastic Agents; Bone Neoplasms; Cathepsin K; Denosumab; Endothelins; Humans; Proto-Oncogene Proteins pp60(c-src); RANK Ligand; Medicine (all); Oncology; Radiology Nuclear Medicine and ImagingInternal medicineMedicineAnimalsHumansRadiology Nuclear Medicine and imagingMolecular targetbiologyAnimalbusiness.industryMedicine (all)EndothelinsRANK LigandCancerBone metastasisAntibodies MonoclonalGeneral Medicinemedicine.diseaseClinical trialBone metastaseDenosumabOncologyRANKLCancer cellbiology.proteinDenosumabbusinessHumanmedicine.drugCancer treatment reviews
researchProduct